Unicycive Therapeutics Targets June 29 OLC Approval After CMO-Driven NDA Resubmission

Unicycive Therapeutics' oxylanthanum carbonate (OLC) NDA resubmission is tracking toward a PDUFA target action date of June 29, 2026, but the path to that date carries a compliance lesson that QA directors and regulatory affairs leads should read carefully. The December 2025 resubmission was necessitated by progress at a third-party manufacturing vendor, meaning the original NDA stalled not on clinical or safety grounds, but on CMC readiness at an external site.

The FDA accepted the resubmission in January 2026 and, notably, raised no concerns over the preclinical, clinical, or safety data included in the original filing. The NDA package draws on three clinical studies, a Phase 1 study in healthy volunteers, a bioequivalence study, and a tolerability study in CKD patients on dialysis, alongside multiple preclinical datasets and chemistry, manufacturing, and controls (CMC) data. That the clinical record remained intact while the manufacturing record required remediation underscores how CMO timelines can decouple from sponsor approval schedules, extending review cycles independent of therapeutic merit.

For plant heads and QA directors managing external manufacturing relationships through NDA cycles, the Unicycive case reinforces the operational risk of insufficient CMO oversight. Under 21 CFR Part 211 and ICH Q10 quality system expectations, sponsors retain accountability for drug product quality regardless of where manufacturing occurs. When a third-party site's readiness determines a resubmission date, the gap between contractual milestones and regulatory-grade process validation becomes a direct approval risk.

Unicycive is advancing commercial infrastructure in parallel with the review, including reimbursement support services through its UniSource hub, targeting the approximately 75% of U.S. dialysis patients with chronic kidney disease who experience uncontrolled hyperphosphatemia. As of May 11, 2026, the company held $57.1 million in cash and marketable securities, with operations funded into 2027. R&D spend fell to $1.6 million in Q1 2026 from $2.2 million in Q1 2025, reflecting reduced drug development and consulting costs, while G&A rose to $6.8 million from $5.8 million, driven by increased professional services and labor ahead of a potential launch.

The June 29 PDUFA date will serve as a measurable checkpoint for how thoroughly the CMC deficiencies identified in the original submission have been resolved to the FDA's satisfaction.

Source: Unicycive Therapeutics, Inc. via GlobeNewswire, May 12, 2026.